- Home
- PRLD vs IPA Comparison
PRLD vs IPA Comparison
Compare PRLD & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- IPA
- Stock Information
- Founded
- PRLD 2016
- IPA 1983
- Country
- PRLD United States
- IPA United States
- Employees
- PRLD N/A
- IPA N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- IPA Health Care
- Exchange
- PRLD Nasdaq
- IPA Nasdaq
- Market Cap
- PRLD 48.6M
- IPA 46.0M
- IPO Year
- PRLD 2020
- IPA 2017
- Fundamental
- Price
- PRLD $0.78
- IPA $1.28
- Analyst Decision
- PRLD Strong Buy
- IPA Strong Buy
- Analyst Count
- PRLD 2
- IPA 2
- Target Price
- PRLD $4.50
- IPA $4.00
- AVG Volume (30 Days)
- PRLD 221.0K
- IPA 5.1M
- Earning Date
- PRLD 08-11-2025
- IPA 07-28-2025
- Dividend Yield
- PRLD N/A
- IPA N/A
- EPS Growth
- PRLD N/A
- IPA N/A
- EPS
- PRLD N/A
- IPA N/A
- Revenue
- PRLD $7,000,000.00
- IPA $16,581,105.00
- Revenue This Year
- PRLD N/A
- IPA $4.67
- Revenue Next Year
- PRLD N/A
- IPA $14.15
- P/E Ratio
- PRLD N/A
- IPA N/A
- Revenue Growth
- PRLD N/A
- IPA 1.34
- 52 Week Low
- PRLD $0.61
- IPA $0.27
- 52 Week High
- PRLD $6.80
- IPA $1.31
- Technical
- Relative Strength Index (RSI)
- PRLD 42.16
- IPA 79.18
- Support Level
- PRLD $0.77
- IPA $1.00
- Resistance Level
- PRLD $0.84
- IPA $1.15
- Average True Range (ATR)
- PRLD 0.07
- IPA 0.13
- MACD
- PRLD -0.02
- IPA 0.02
- Stochastic Oscillator
- PRLD 16.04
- IPA 100.00
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.